SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending due to intense community debate surrounding Donald Trump's State of the Union address, as many speculate whether the speech will ignite a rally, given the stock often acts as a proxy for his political sentiment, or further its decline amid discussions of his legal issues and economic policies.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending as the community speculates intensely on potential market-moving comments from a political address, while also closely watching an upcoming major AI chipmaker's earnings report for broader market direction.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is rallying as the community anticipates significant recognition for its groundbreaking cancer therapies, spurred by Dr. Patrick Soon-Shiong's compelling presentations and extreme short interest fueling discussions of an imminent squeeze.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is at the center of market attention ahead of its highly anticipated Q4 earnings report, with community discussion intensely focused on whether a potential blowout performance will propel the stock to new highs or trigger a "sell the news" event. This uncertainty is heightened by ongoing debates about AI spending, market maker influence, and concerns over China export controls.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending following a mixed earnings report, which highlighted revenue growth but wider losses, alongside news of significant layoffs. The community is sharply divided between those anticipating a short squeeze and future product success, and those highlighting persistent cash burn and the potential for further dilution.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending amidst a high-stakes bidding war for Warner Bros. Discovery, as WBD's board deems a higher Paramount Skydance offer potentially superior, giving Netflix a four-day window to respond. The community is fiercely debating if Netflix should raise its bid, risking further dilution, or walk away to collect a significant breakup fee, with added political scrutiny impacting the decision.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is actively discussed as the market anticipates potential catalysts from the State of the Union address and NVIDIA's upcoming earnings, driving widespread community speculation on whether these events will lead to a market rally or a significant pullback amidst persistent claims of manipulation.

Corning, Inc. engages in the provision of glass for notebook computers, flat panel desktop monitors, display televisions, and other information display applications, carrier network and enterprise network products for the telecommunications industry, ceramic substrates for gasoline and diesel engines in automotive and heavy-duty vehicle markets, laboratory products for the scientific community and polymer products for biotechnology applications, optical materials for the semiconductor industry and the scientific community, and polycrystalline silicon products and other technologies. It operates through the following segments: Optical Communications, Display Technologies, Specialty Materials, Environmental Technologies, and Life Sciences. The Optical Communications segment is classified into two main product groupings: carrier and enterprise network. The carrier network group consists of products and solutions for optical-based communications infrastructure for services such as video, data, and voice communications. The enterprise network group consists primarily of optical-based communication networks sold to businesses, governments, and individuals for their own use. The Display Technologies segment manufactures glass substrates for flat panel displays, including organic light-emitting diodes and liquid crystal displays that are used primarily in televisions, notebook computer, desktop monitors, tablets, and handheld devices. The Specialty Materials segment is involved in the manufacture of products that provide material formulations for glass, glass ceramics and crystals, and precision metrology instruments and software. The Environmental Technologies segment focuses on manufacturing ceramic substrates and filter products for emissions control in mobile applications. The Life Sciences segment develops, manufactures, and supplies laboratory products. The company was founded by Amory Houghton Sr. in 1851 and is headquartered in Corning, NY.

Corning, Inc.

Corning (GLW) is soaring following a $6 billion multi-year agreement with Meta Platforms to supply fiber-optic solutions for AI data centers, positioning it as a key "picks and shovels" play in the burgeoning AI infrastructure. The community is highly bullish, anticipating further hyperscaler contracts and analyst upgrades, as demand for optical fiber drives the stock to multi-decade highs.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA Group is trending following its earnings report, which showcased strong revenue growth and new restaurant openings for fiscal 2025, alongside a positive outlook for fiscal 2026. The community is actively debating its high valuation and moderated same-store sales growth against its aggressive expansion strategy and perceived market share gains over competitors like Chipotle.

First Solar, Inc. is a solar technology company, which engages in the provision of solar modules. It is involved in the design, manufacture, and sale of cadmium tellurid (CdTe) solar modules, which convert sunlight into electricity. The company was founded by Michael J. Ahearn in 1999 and is headquartered in Tempe, AZ.

First Solar Inc

First Solar is trending after strong earnings were met with lower-than-expected 2026 sales guidance, triggering a sharp sell-off and community debate over the outlook, with bulls highlighting its U.S. manufacturing and competitive edge for growing energy demand, while bears focus on the near-term revenue concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Merck is currently seeking to fortify its drug portfolio before its blockbuster cancer therapy Keytruda begins to lose patent protection in 2028.</li><li>While there were reports of Merck looking to acquire cancer drugmaker Revolution Medicines in January for about $30 billion, a deal didn’t materialize.</li><li>MoonLake Therapeutics, headquartered in Switzerland, is developing its investigational therapy sonelokimab for the treatment of inflammatory diseases.</li></ul>Shares of MoonLake Immunotherapeutics (MLTX) garnered retail attention on Tuesday amid buyout speculation.On Stocktwits, a retail investor voiced optimism for either a buyout announcement or positive news from the U.S. Food and Drug Administration for the company this week.<stembedurl>https://www.stocktwits.com/Warren_8/message/645090086</stembedurl>Another user, however, said that MoonLake must increase its share price from current levels if it wants to be acquired.<stembedurl>https://www.stocktwits.com/Newcar/message/645134185</stembedurl>Some users also highlighted a potential takeover by pharma major Merck for MoonLake.<stembedurl>https://www.stocktwits.com/Bigpapa46/message/645006814</stembedurl>On Stocktwits, overall retail sentiment around MLTX improved from ‘extremely bearish’ to ‘bearish’ territory over the past 24 hours, while message volume remained at ‘low’ levels.Shares of the company closed 11% higher in the regular trading session. &nbsp;<h2 class="st-heading-2">Is Merck Looking To Acquire Companies?</h2>Merck is currently seeking to fortify its drug portfolio before its blockbuster cancer therapy Keytruda begins to lose patent protection in 2028. Keytruda generated approximately $29.5 billion in global sales for the full year 2024, accounting for about 46% of the company’s overall worldwide sales.The company entered into a deal to acquire Cidara Therapeutics for about $9.2 billion in November. It also agreed to buy respiratory drug developer Verona Pharma for $10 billion in July as part of a broader effort to maintain revenue momentum.While there were reports of Merck looking to acquire cancer drugmaker Revolution Medicines in January for about $30 billion, a deal didn’t materialize as the two companies failed to come to an agreement on price, The Wall Street Journal reported.<h2 class="st-heading-2">MoonLake’s Portfolio</h2>MoonLake Therapeutics, headquartered in Switzerland, is developing its investigational therapy sonelokimab for the treatment of inflammatory diseases such as hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis and palmoplantar pustulosis.Earlier this month, the FDA granted Fast Track designation to sonelokimab in moderate-to-severe palmoplantar pustulosis. The company is also eyeing making an application to the FDA for approval of sonelokimab in hidradenitis suppurativa in the second half of 2026.The company is now slated to hold an investor day event on Feb. 23, 2026.<a href="https://stocktwits.com/symbol/MLTX">MLTX stock</a> has dropped 59% this year.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/help-stock-rallies-after-experimental-depression-drug-reduces-symptoms-in-study/cZRWDUOR4HP">HELP Stock Rallies After Experimental Depression Drug Reduces Symptoms In Study: Retail Thinks Its ‘Time To Buy More’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the MoonLake Immunotherapeutics (Moon Lake) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

MLTX Stock Gains As Retail Eyes Buyout From Big Pharma, Upcoming Investor Day Event

Some Stocktwits users voiced optimism for the inflammation-drug maker getting acquired by pharma giant Merck. 

Equity

<ul class="summary-bullets"><li>H.C. Wainwright raised MoonLake’s price target to $32 from $26 and maintained a ‘Buy’ rating.</li><li>BTIG said the FDA approval ‘clears a significant overhang’ for MoonLake’s clinical program.</li><li>MoonLake plans to submit its biologics license application in the second half of 2026.</li></ul>MoonLake Immunotherapeutics (MLTX) remained on investors’ radar after its shares rose 5% in premarket trading on Friday, following favorable brokerage action tied to positive feedback from the U.S. Food and Drug Administration (FDA) on its treatment for hidradenitis suppurativa, a chronic inflammatory skin condition.<a href="https://stocktwits.com/symbol/MLTX">MLTX</a> was among the top trending tickers on Stocktwits at the time of writing.BTIG upgraded MoonLake Immunotherapeutics to ‘Buy’ from ‘Neutral’ and set a $24 price target, citing a recent regulatory update, according to TheFly.<h2 class="st-heading-2">The FDA Feedback</h2>The FDA <a href="https://stocktwits.com/news-articles/markets/equity/why-did-mltx-stock-jump-45-in-pre-market-today/cmUbJFWR4Pt">confirmed</a> that MoonLake can establish the effectiveness of Sonelokimab (SLK) in hidradenitis suppurativa without additional trials, a development BTIG believes clears a significant overhang for the company’s clinical program and could position SLK for FDA approval.This would be supported by existing data from the VELA-1, VELA-2, and MIRA studies. The company plans to submit its biologics license application in the second half of 2026.H.C. Wainwright raised MoonLake’s price target to $32 from $26 and maintained a ‘Buy’ rating. The company’s FDA meeting outcome delineates a path to registration, the firm said.The stock closed 27% higher on Thursday following the FDA feedback.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits remained in the ‘extremely bullish’ zone over the past 24 hours, accompanied by ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/MLTX_jpg_6f56883898.webp" alt="MLTX.jpg">One user sees potential conversations regarding mergers and acquisitions following the FDA feedback.<stembedurl>https://stocktwits.com/Atdanaiw/message/641311151</stembedurl>Another user believes MLTX’s value needs to grow further before a probable acquisition.<stembedurl>https://stocktwits.com/Newcar/message/641308484</stembedurl>MoonLake had reportedly turned down a $3 billion acquisition offer from Merck (MRK) in June last year.The stock has been under heavy selling pressure over the past year, declining more than 70%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/glue-stock-slips-pre-market-after-pricing-300-million-public-offer-at-discount/cmU2ghYR4dQ">GLUE Stock Slips Pre-Market After Pricing $300 Million Public Offer At Discount</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

MLTX Stock Extends Rally As FDA Feedback Spurs Bullish Brokerage Action – Retail Speculates On Potential M&A Conversations

BTIG upgraded MoonLake Immunotherapeutics to ‘Buy’ from ‘Neutral’ after the FDA said the company could show the effectiveness of Sonelokimab without additional HS trials.

<ul class="summary-bullets"><li>The FDA feedback indicates the company can establish&nbsp;substantial evidence of effectiveness without conducting additional&nbsp;hidradenitis suppurativa trials.</li><li>The firm remains on track to submit its Biologic License Application for Sonelokimab in the second half of 2026.</li><li>MoonLake will host an Investor Day on February 23 to review FDA feedback from the Type B meeting.</li></ul>Shares of MoonLake Immunotherapeutics (MLTX) surged 45% in premarket trading on Thursday after the company said it received positive regulatory feedback from the U.S. Food and Drug Administration (FDA) following a Type B meeting regarding Sonelokimab (SLK), a drug used to treat hidradenitis suppurativa (HS), a chronic inflammatory skin disorder.The FDA feedback indicates the company can establish substantial evidence of effectiveness (SEE) without conducting additional HS trials, using a Biologic License Application (BLA) supported by data from its existing VELA-1, VELA-2, and MIRA studies.The agency advised including MIRA results to support efficacy and submitting VELA-2 data to inform the safety profile. Based on the official meeting outcome, the company remains on track to submit its BLA for Sonelokimab in the second half of 2026.“The positive outcome of our Type B meeting with the FDA provides the clarity needed to support a pathway to approval for our existing HS program, with no additional clinical trials required. In addition, the fact that we can prepare the BLA with the wealth of data across the VELA and MIRA trials provides us and the FDA with flexibility to determine the best label possible, so that SLK, if approved, can have the most positive impact for HS patients,” said Jorge Santos da Silva, Founder and Chief Executive Officer at MoonLake Immunotherapeutics.<h2 class="st-heading-2">2026 Pipeline</h2>MoonLake will host an Investor Day on Feb. 23, 2026, to review the FDA feedback from the Type B meeting and share new clinical data for SLK across indications, along with updates to its 2026 catalyst outlook.The company also expects a steady flow of clinical readouts over the next year, including Phase 2 data in axial spondyloarthritis and multiple Phase 3 updates in psoriatic arthritis and HS. Key milestones include a Phase 2 axSpA readout in Q1 2026, several Phase 3 readouts by mid-2026, and a planned BLA submission in the second half of 2026.<h2 class="st-heading-2">How Did Stockwits Users React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘high’ message volumes. <a href="https://stocktwits.com/symbol/MLTX">MLTX</a> was among the top trending stocks on the platform at the time of writing.<figure class="image"><img src="https://news.stocktwits-cdn.com/MLTX_jpg_70c33bd6fe.webp" alt="MLTX.jpg" width="916" height="96"><figcaption>MLTX's Sentiment Meter and Message Volumes at Premarket on Jan. 8, 2026 | Source: Stocktwits</figcaption></figure>One user expects the stock to climb to $22 within a few sessions. It is currently trading at $16.2.<stembedurl>https://stocktwits.com/discountcroesus1/message/641193716</stembedurl>The stock has been under heavy selling pressure over the past year, declining nearly 80%.Read Also: <a href="https://stocktwits.com/news-articles/markets/equity/why-vnda-stock-falling-premarket/cmUbEA9R4Pn">Vanda Stock Drops 10% Premarket After FDA Rejects Jet Lag Drug Application</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a MoonLake Immunotherapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Why Did MLTX Stock Jump 45% In Pre-Market Today?

The company said it received positive regulatory feedback from the U.S. FDA following a Type B meeting regarding a drug used to treat hidradenitis suppurativa, a chronic inflammatory skin disorder.

BlackRock Institutional Trust Company N.A. - iShares ESG Aware MSCI USA Small-Cap ETF

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

Ahead of earnings, sentiment is split between blowout AI growth and concerns around macro pressure, positioning, and post-ER volatility. How do you see it playing out?

Current Price	$49.86
Prev Close	$49.37
Open	$49.44
Dividend Yield	N/A
50-Day Moving Average	$48.33
Beta	N/A
Avg. Volume	179,939.30
PE Ratio	N/A

52-Week High	$50.47
52-Week Low	$32.91
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

ESML
iShares ESG Aware MSCI USA Small-Cap ETF

Feed

News

Sentiment

Fundamentals

Info

Latest ESML News

ESMLiShares ESG Aware MSCI USA Small-Cap ETF